TP53 and cancer: Our results also suggest that MutSα-deficiency is linked with an accelerated somatic mutation rate at cancer driver hotspots within TP53. We hypothesise that CpG hypermutation may bias the somatic mutational landscape, which can cause the selection of somatic driver mutations at methylated CpGs and within key protein domains such as the TP53 DNA binding domain.